|
1
|
Gao SZ, Chaparro SV, Perlroth M, Montoya
JG, Miller JL, DiMiceli S, Hastie T, Oyer PE and Schroeder J:
Post-transplantation lymphoproliferative disease in heart and
heart-lung transplant recipients: 30-year experience at Stanford
University. J Heart Lung Transplant. 22:505–514. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Taylor AL, Marcus R and Bradley JA:
Post-transplant lymphoproliferative disorders (PTLD) after solid
organ transplantation. Crit Rev Oncol Hematol. 56:155–167. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wasson S, Zafar MN, Best J and Reddy HK:
Post-transplantation lymphoproliferative disorder in heart and
kidney transplant patients: A single-center experience. J
Cardiovasc Pharmacol Ther. 11:77–83. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khedmat H, Alavian S and Taheri S:
Significance of Epstein-Barr virus infection in the outcome of
renal transplant patients with lymphoproliferative disorders. Ann
Transplant. 15:40–44. 2010.PubMed/NCBI
|
|
5
|
Poirel HA, Bernheim A, Schneider A, Meddeb
M, Choquet S, Leblond V, Charlotte F, Davi F, Canioni D, Macintyre
E, et al: Characteristic pattern of chromosomal imbalances in
posttransplantation lymphoproliferative disorders: Correlation with
histopathological subcategories and EBV status. Transplantation.
80:176–184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsai DE, Hardy CL, Tomaszewski JE, Kotloff
RM, Oltoff KM, Somer BG, Schuster SJ, Porter DL, Montone KT and
Stadtmauer EA: Reduction in immunosuppression as initial therapy
for posttransplant lymphoproliferative disorder: Analysis of
prognostic variables and long-term follow-up of 42 adult patients.
Transplantation. 71:1076–1088. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herman J, Vandenberghe P, van den Heuvel
I, Van Cleemput J, Winnepenninckx V and Van Damme-Lombaerts R:
Successful treatment with rituximab of lymphoproliferative disorder
in a child after cardiac transplantation. J Heart Lung Transplant.
21:1304–1309. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Campo E, Swerdlow SH, Harris NL, Pileri S,
Stein H and Jaffe ES: The 2008 WHO classification of lymphoid
neoplasms and beyond: Evolving concepts and practical applications.
Blood. 117:5019–5032. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barnard CN: The first transplantation of a
human heart. Presse Med. 75:2815–2816. 1967.(In French). PubMed/NCBI
|
|
10
|
Marker SC, Ascher NL, Kalis JM, Simmons
RL, Najarian JS and Balfour HH Jr: Epstein-Barr virus antibody
responses and clinical illness in renal transplant recipients.
Surgery. 85:433–440. 1979.PubMed/NCBI
|
|
11
|
Kinch A, Baecklund E, Backlin C, Ekman T,
Molin D, Tufveson G, Fernberg P, Sundström C, Pauksens K and Enblad
G: A population-based study of 135 lymphomas after solid organ
transplantation: The role of Epstein-Barr virus, hepatitis C and
diffuse large B-cell lymphoma subtype in clinical presentation and
survival. Acta Oncol. 53:669–679. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yousem SA, Randhawa P, Locker J, Paradis
IL, Dauber JA, Griffith BP and Nalesnik MA: Posttransplant
lymphoproliferative disorders in heart-lung transplant recipients:
Primary presentation in the allograft. Hum Pathol. 20:361–369.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gupta S, Fricker FJ, González-Peralta RP,
Slayton WB, Schuler PM and Dharnidharka VR: Post-transplant
lymphoproliferative disorder in children: Recent outcomes and
response to dual rituximab/low-dose chemotherapy combination.
Pediatr Transplant. 14:896–902. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weissmann DJ, Ferry JA, Harris NL, Louis
DN, Delmonico F and Spiro I: Posttransplantation
lymphoproliferative disorders in solid organ recipients are
predominantly aggressive tumors of host origin. Am J Clin Pathol.
103:748–755. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schubert S, Abdul-Khaliq H, Lehmkuhl HB,
Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K,
Gross-Wieltsch U, Hetzer R and Berger F: Diagnosis and treatment of
post-transplantation lymphoproliferative disorder in pediatric
heart transplant patients. Pediatr Transplant. 13:54–62. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shan D, Ledbetter JA and Press OW:
Apoptosis of malignant human B cells by ligation of CD20 with
monoclonal antibodies. Blood. 91:1644–1652. 1998.PubMed/NCBI
|
|
17
|
Trofe J, Buell JF, Beebe TM, Hanaway MJ,
First MR, Alloway RR, Gross TG, Succop P and Woodle ES: Analysis of
factors that influence survival with post-transplant
lymphoproliferative disorder in renal transplant recipients: The
Israel Penn International Transplant Tumor Registry experience. Am
J Transplant. 5:775–780. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khedmat H and Taheri S: Early versus late
outset of lymphoproliferative disorders post-heart and lung
transplantation: The PTLD. Int Survey. Hematol Oncol Stem Cell
Ther. 4:10–16. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Webber SA, Naftel DC, Fricker FJ,
Olesnevich P, Blume ED, Addonizio L, Kirklin JK and Canter CE:
Pediatric Heart Transplant Study: Lymphoproliferative disorders
after paediatric heart transplantation: A multi-institutional
study. Lancet. 367:233–239. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Au WY, Lie AK, Kwong YL, Shek TW, Hawkins
BR, Lai KN, Tang SC, Lo CM, Fan ST, Liu CL, et al:
Post-transplantation lymphoproliferative disease in Chinese: The
Queen Mary Hospital experience in Hong Kong. Leuk Lymphoma.
43:1403–1407. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garrett TJ, Chadburn A, Barr ML, Drusin
RE, Chen JM, Schulman LL, Smith CR, Reison DS, Rose EA and Michler
RE: Posttransplantation lymphoproliferative disorders treated with
cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy.
Cancer. 72:2782–2785. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choquet S, Trappe R, Leblond V, Jäger U,
Davi F and Oertel S: CHOP-21 for the treatment of post-transplant
lymphoproliferative disorders (PTLD) following solid organ
transplantation. Haematologica. 92:273–274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Windebank K, Walwyn T, Kirk R, Parry G,
Hasan A, Bown N and Wilkins B: Post cardiac transplantation
lymphoproliferative disorder presenting as t(8;14) Burkitt
leukaemia/lymphoma treated with low intensity chemotherapy and
rituximab. Pediatr Blood Cancer. 53:392–396. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gross TG, Hinrichs SH, Winner J, Greiner
TC, Kaufman SS, Sammut PH and Langnas AN: Treatment of
post-transplant lymphoproliferative disease (PTLD) following solid
organ transplantation with low-dose chemotherapy. Ann Oncol.
9:339–340. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Harris N, Swerdlow SH, Frizzera G and
Knowles DM: Post-transplant lymphoproliferative disorders. IARC
Press. Cheenra: 2001.
|
|
26
|
Milpied N, Vasseur B, Parquet N, Garnier
JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot
B, et al: Humanized anti-CD20 monoclonal antibody (Rituximab) in
post transplant B-lymphoproliferative disorder: A retrospective
analysis on 32 patients. Ann Oncol. 11(Suppl 1): 113–116. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oertel SH, Anagnostopoulos I, Bechstein
WO, Liehr H and Riess HB: Treatment of posttransplant
lymphoproliferative disorder with the anti-CD20 monoclonal antibody
rituximab alone in an adult after liver transplantation: A new drug
in therapy of patients with posttransplant lymphoproliferative
disorder after solid organ transplantation? Transplantation.
69:430–432. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Verschuuren EA, Stevens SJ, van Imhoff GW,
Middeldorp JM, de Boer C, Koëter G, The TH and van Der Bij W:
Treatment of posttransplant lymphoproliferative disease with
rituximab: The remission, the relapse and the complication.
Transplantation. 73:100–104. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Orjuela M, Gross TG, Cheung YK, Alobeid B,
Morris E and Cairo MS: A pilot study of chemoimmunotherapy
(cyclophosphamide, prednisone and rituximab) in patients with
post-transplant lymphoproliferative disorder following solid organ
transplantation. Clin Cancer Res. 9:3945S–3952S. 2003.PubMed/NCBI
|
|
30
|
Kusuki S, Hashii Y, Fukushima N, Takizawa
S, Tokimasa S, Kogaki S, Ohta H, Tsuda E, Nakagawa A and Ozono K:
Pediatric post-transplant diffuse large B cell lymphoma after
cardiac transplantation. Int J Hematol. 89:209–213. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boyle GJ, Michaels MG, Webber SA, Knisely
AS, Kurland G, Cipriani LA, Griffith BP and Fricker FJ:
Posttransplantation lymphoproliferative disorders in pediatric
thoracic organ recipients. J Pediatr. 131:309–313. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cohen AH, Sweet SC, Mendeloff E, Mallory
GB Jr, Huddleston CB, Kraus M, Kelly M, Hayashi R and DeBaun MR:
High incidence of posttransplant lymphoproliferative disease in
pediatric patients with cystic fibrosis. Am J Respir Crit Care Med.
161:1252–1255. 2000. View Article : Google Scholar : PubMed/NCBI
|
